Current Cardiology Reports

, 21:98 | Cite as

Current Role of the CardioMEMS Device for Management of Patients with Heart Failure

  • Calvin C. LeungEmail author
New Therapies for Cardiovascular Disease (AA Bavry, Section Editor)
Part of the following topical collections:
  1. Topical Collection on New Therapies for Cardiovascular Disease


Purpose of Review

Heart failure (HF) remains a significant burden to our healthcare system and a leading cause of hospitalizations. Current reactive strategies to treat and manage HF have failed to reduce hospitalizations and improve survival. The CardioMEMS device has recently been demonstrated to improve quality of life in HF and reduce HF-related hospitalizations. Current HF management strategies are reviewed with a particular emphasis on the current role of the CardioMEMS device.

Recent Findings

The CHAMPION trial is the only randomized trial looking at the CardioMEMS device. Patients managed with targeted pulmonary artery pressures resulted in 28% reduction in the primary end-point of HF-related hospitalization at 6 months (HR 0.72, 95% CI 0.60–0.85, p = 0.0002) and 37% reduction during the entire follow-up period, which averaged 15 months (HR 0.63, 95% CI 0.52–0.77, p < 0.0001). The prospective open-label post-approval study recently presented a 58% reduction in HF hospitalizations per patient year (HR 0.42, 95% CI 0.38–0.47, p < 0.0001).


Management of HF using the CardioMEMS device has been shown to reduce HF hospitalizations and improve quality of life regardless of ejection fraction. Patients best suited for this device are those with recurrent congestive symptoms despite optimal medical therapy.


CardioMEMS Heart failure Pulmonary artery pressure Implantable hemodynamic monitor 


Compliance with Ethical Standards

Conflict of Interest

Calvin C. Leung declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528. Scholar
  2. 2.
    Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19. Scholar
  3. 3.
    Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation. 2006;113(6):799–805.CrossRefGoogle Scholar
  4. 4.
    Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101(7):1016–22. Scholar
  5. 5.
    Cowie MR, Fox KF, Wood DA, et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002;23(11):877–85.CrossRefGoogle Scholar
  6. 6.
    Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344–50.CrossRefGoogle Scholar
  7. 7.
    Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med. 2008;168(4):418–24. Scholar
  8. 8.
    Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000–2010. NCHS data brief, no 108. Hyattsville, MD: National Center for Health Statistics. NCHS Data Brief. 2012;(108):1–8.Google Scholar
  9. 9.
    Yancy CW, Lopatin M, Stevenson LW, de Marco T, Fonarow GC, ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol. 2006 Jan 3;47(1):76–84.CrossRefGoogle Scholar
  10. 10.
    Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–16.CrossRefGoogle Scholar
  11. 11.
    Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail. 2015;8(4):741–8. Scholar
  12. 12.
    Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646–59. Scholar
  13. 13.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. Scholar
  14. 14.
    Lee DS, Austin PC, Stukel TA, Alter DA, Chong A, Parker JD, et al. “Dose-dependent” impact of recurrent cardiac events on mortality in patients with heart failure. Am J Med. 2009;122(2):162–169.e1. Scholar
  15. 15.
    Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260–6.CrossRefGoogle Scholar
  16. 16.
    Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118(14):1433–41. Scholar
  17. 17.
    Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr Heart Fail Rep. 2009;6(4):287–92.CrossRefGoogle Scholar
  18. 18.
    Capomolla S, Ceresa M, Pinna G, Maestri R, la Rovere MT, Febo O, et al. Echo-Doppler and clinical evaluations to define hemodynamic profile in patients with chronic heart failure: accuracy and influence on therapeutic management. Eur J Heart Fail. 2005;7(4):624–30.CrossRefGoogle Scholar
  19. 19.
    Lewin J, Ledwidge M, O'Loughlin C, McNally C, McDonald K. Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail. 2005;7(6):953–7.CrossRefGoogle Scholar
  20. 20.
    Abraham WT, Compton S, Haas G, Foreman B, Canby RC, Fishel R, et al. Intrathoracic impedance vs. daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest Heart Fail. 2011;17(2):51–5. Scholar
  21. 21.
    Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, et al. Telemonitoring in patients with heart failure. N Engl J Med. 2010;363(24):2301–9. Scholar
  22. 22.
    Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Böhm M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation. 2011;123(17):1873–80. Scholar
  23. 23.
    Roberts E, Ludman A, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910. Scholar
  24. 24.
    Pufulete M, Maishman R, Dabner L, Higgins JPT, Rogers CA, Dayer M, et al. B-type natriuretic peptide-guided therapy for heart failure: a systematic review and meta-analysis of individual participant data (IPD) and aggregate data. Syst Rev. 2018;7(1):112. Scholar
  25. 25.
    Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–92. Scholar
  26. 26.
    Desai AS. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long. Circulation. 2013;127(4):509–16; discussion 516. Scholar
  27. 27.
    Steimle AE, Stevenson LW, Chelimsky-Fallick C, Fonarow GC, Hamilton MA, Moriguchi JD, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997;96:1165–72.CrossRefGoogle Scholar
  28. 28.
    Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294(13):1625–33.CrossRefGoogle Scholar
  29. 29.
    Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. Eur Heart J. 2011;32(18):2266–73. Scholar
  30. 30.
    Yu CM, Wang L, Chau E, Chan RHW, Kong SL, Tang MO, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112(6):841–8.CrossRefGoogle Scholar
  31. 31.
    Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol. 2010;55(17):1803–10. Scholar
  32. 32.
    van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation. 2011;124(16):1719–26. Scholar
  33. 33.
    Perego GB, Oldani M, Pellegrini D, Brasca FMA, Malfatto G, Villani A, et al. Correlation between pulmonary artery pressure and thoracic impedance: insights from daily monitoring through an implanted device in chronic heart failure. Int J Cardiol. 2017;245:196–200. Scholar
  34. 34.
    Abraham WT, Adamson PB, Costanzo MR, et al. Hemodynamic monitoring in advanced heart failure: results from the LAPTOP-HF trial. Late-Breaking Clinical Trials. Presented at HFSA 2016. Orlando, FL; J Card Fail. 2016;22(11): 940. DOI: CrossRefGoogle Scholar
  35. 35.
    Hubbert L, Baranowski J, Delshad B, et al. Left atrial pressure monitoring with an implantable wireless pressure sensor after implantation of a left ventricular assist device. ASAIO J. 2017;63(5):e60–5. Scholar
  36. 36.
    Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008;51(11):1073–9. Scholar
  37. 37.
    Stevenson LW, Zile MR, Bennett TD, Kueffer FJ, Jessup ML, Adamson P, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010;3:580–7.CrossRefGoogle Scholar
  38. 38.
    Adamson PB, Abraham WT, Aaron M, et al. CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. J Card Fail. 2011;17(1):3–10. Scholar
  39. 39.
    Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658–66. Scholar
  40. 40.
    Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935–44. Scholar
  41. 41.
    • Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet. 2016;387(10017):453–61. This is the only current randomized trial looking at the CardioMEMS device.CrossRefPubMedGoogle Scholar
  42. 42.
    Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G, et al. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70(15):1875–86. Scholar
  43. 43.
    Desai AS, Bhimaraj A, Bharmi R, Jermyn R, Bhatt K, Shavelle D, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol. 2017;69(19):2357–65. Scholar
  44. 44.
    Muthiah Vaduganathan M, Deflippis EM, Fonarow GC, et al. Postmarketing adverse events related to the CardioMEMS HF system. JAMA Cardiol. 2017;2(11):1277–9. Scholar
  45. 45.
    Shavelle DM. Pulmonary artery pressure-guided therapy for ambulatory heart failure patients in clinical practice: 1-year outcomes from the CardioMEMS post-approval study. Presented at: ACC 2019. New Orleans, LA; 2019.Google Scholar
  46. 46.
    Joly JM, Heywood JT, Shavelle D et al. Front-loaded intervention during first 90 days of pulmonary pressure guided management. Presented at HFSA 2017. Dallas, TX. J Card Fail. 2017;23 (8): Supplement S12–S13. CrossRefGoogle Scholar
  47. 47.
    Ollendorf DA, Sandhu AT, Chapman R, et al. CardioMEMS™ HF System (St. Jude Medical) and sacubitril/valsartan (Entresto™, Novartis) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks. Institute for Clinical and Economic Review. Accessed 28 May 2019
  48. 48.
    Sandhu AT, Goldhaber-Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA. Cost-effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. JACC Heart Fail. 2016;4(5):368–75.CrossRefGoogle Scholar
  49. 49.
    Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2304–22.CrossRefGoogle Scholar
  50. 50.
    Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Liu Y, Mehra MR, et al. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF. J Am Heart Assoc. 2012;1(1):16–26. Scholar
  51. 51.
    Tran RH, Aldemerdash A, Chang P, Sueta CA, Kaufman B, Asafu-adjei J, et al. Guideline-directed medical therapy and survival following hospitalization in patients with heart failure. Pharmacotherapy. 2018;38(4):406–16. Scholar
  52. 52.
    Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for HF with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351–66.CrossRefGoogle Scholar
  53. 53.
    Yancy CW, Januzzi JL, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol. 2018;l 71:201–30.CrossRefGoogle Scholar
  54. 54.
    Choi KH, Choi JO, Jeon ES, et al. Guideline-directed medical therapy for patients with heart failure with midrange ejection fraction: a patient-pooled analysis from the KorHF and KorAHF registries. J Am Heart Assoc. 2018;7(21).
  55. 55.
    • Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975 This is the first guideline to incorporate the use of CardioMEMS in the management of HF. CrossRefGoogle Scholar
  56. 56.
    Angermann CE, Assmus B, Anker SD, Brachmann J, Ertl G, Köhler F, et al. Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). Clin Res Cardiol. 2018;107(11):991–1002. Scholar
  57. 57.
    Lindenfeld J, Abraham WT, Maisel A, Zile M, Smart F, Costanzo MR, et al. Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). Am Heart J. 2019;214:18–27. Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2019

Authors and Affiliations

  1. 1.Section of Cardiology, Department of MedicineOrlando VA Medical CenterOrlandoUSA

Personalised recommendations